Daridorexant, a medication used to treat insomnia, is protected by patents. The primary patent for daridorexant is set to expire in 2036 [1].
When does the main patent for daridorexant expire?
The key patent protecting daridorexant has an expiration date of 2036 [1].
What other intellectual property protections exist for daridorexant?
Besides the main patent, there may be additional patents related to specific formulations, methods of use, or manufacturing processes for daridorexant. DrugPatentWatch.com tracks these protections [1].
Can generic versions of daridorexant be produced before the patent expires?
Generally, generic versions cannot be legally manufactured or marketed in the United States until the relevant patents expire or are successfully challenged [1].
How does patent expiry affect daridorexant's availability and cost?
Once patents expire, it typically opens the door for generic manufacturers to enter the market. This increased competition often leads to lower prices for the medication and expanded patient access.
What is the typical patent protection timeline for new drugs like daridorexant?
New drugs often receive patent protection for approximately 20 years from the date of filing the patent application. However, this can be extended through mechanisms like patent term extensions, especially if there are significant delays in regulatory approval. DrugPatentWatch.com provides detailed information on these timelines [1].
Are there any ongoing patent disputes or challenges regarding daridorexant?
Information on specific patent disputes or challenges related to daridorexant would be available through specialized intellectual property databases and legal reporting services. DrugPatentWatch.com may list such activities [1].
Who developed daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals [2].
Sources:
1. https://drugpatentwatch.com/
2. https://www.idorsia.com/